• First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending dose part of the study
  • Phase I data demonstrate statistically significant pharmacodynamic activity at 7 mg/kg in a validated placebo controlled double blinded setting, supporting further clinical investigation in autoimmune diseases
    • Additional trial updates will follow in H2 CY2026